البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
LACOSAMIDE
PHARMASCIENCE INC
N03AX18
LACOSAMIDE
150MG
TABLET
LACOSAMIDE 150MG
ORAL
60
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0152810003; AHFS:
APPROVED
2018-10-01
______________________________________________________________________________ _pharma-LACOSAMIDE Product Monograph_ _ Page 1 of 44_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PHARMA-LACOSAMIDE Lacosamide Tablets Tablets; 50 mg, 100 mg, 150 mg and 200 mg, Oral Ph.Eur. Antiepileptic Agent ATC Code: N03AX18 PHARMASCIENCE INC.: 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 273596 Date of Initial Authorization: OCT 1, 2018 Date of Revision: APR 14, 2023 ______________________________________________________________________________ _pharma-LACOSAMIDE Product Monograph_ _ Page 2 of 44_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, 7.1.1 Pregnant Women 04/2023 7 Warnings and Precautions, 7.1.2 Breast-feeding 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1. INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2. CONTRAINDICATIONS ................................................................................................. 4 4. DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations .............................................................................................. 4 4.2 Recommende اقرأ الوثيقة كاملة